Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

Anstee Quentin M.; Neuschwander-Tetri Brent A.; Wong Vincent Wai-Sun; Abdelmalek Manal F.; Younossi Zobair M.; Yuan Jiacheng; Pecoraro Maria Lucia; Seyedkazemi Star; Fischer Laurent; Bedossa Pierre; Goodman Zachary; Alkhouri Naim; Tacke Frank; Sanyal Arun

首页> 外文期刊>Contemporary clinical trials >Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

【24h】

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

机译：CENICRIVIROC用于治疗非酒精脂肪肝炎的成人肝纤维化：极光第3期研究设计

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Nonalcoholic steatohepatitis (NASH) is a sub-classification of nonalcoholic fatty liver disease (NAFLD) characterized by increased risk of progressive liver fibrosis. Cenicriviroc (CVC) is a novel, orally administered, potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with NASH.

机译：简介：非酒精性脱脂性（NASH）是非酒精性脂肪肝疾病（NAFLD）的亚分类，其特征是进步性肝纤维化的风险增加。 CENICRIVIROC（CVC）是目前在肿瘤中治疗成人肝纤维化的新型，口服助剂的趋化因子2和5受体拮抗剂。

著录项

来源
《Contemporary clinical trials》 |2020年第2020期|共7页
作者
Anstee Quentin M.; Neuschwander-Tetri Brent A.; Wong Vincent Wai-Sun; Abdelmalek Manal F.; Younossi Zobair M.; Yuan Jiacheng; Pecoraro Maria Lucia; Seyedkazemi Star; Fischer Laurent; Bedossa Pierre; Goodman Zachary; Alkhouri Naim; Tacke Frank; Sanyal Arun;
展开▼
作者单位

Newcastle Univ Med Sch Inst Translat &

Clin Res 4th Floor William Leech Bldg Framlington Pl;

St Louis Univ Div Gastroenterol &

Hepatol 3635 Vista Ave St Louis MO 63110 USA;

Chinese Univ Hong Kong Prince Wales Hosp Dept Med &

Therapeut Shatin 9-F Lui Che Woo Clin Sci;

Duke Univ 40 Duke Med Circle Durham NC 27710 USA;

Ctr Liver Dis Inova Fairfax Med Campus 3300 Gallows Rd Falls Church VA 22042 USA;

Allergan Plc 2525 Dupont Dr Irvine CA 92612 USA;

Allergan Plc 701 Gateway Blvd San Francisco CA 94080 USA;

Allergan Plc 701 Gateway Blvd San Francisco CA 94080 USA;

Allergan Plc 701 Gateway Blvd San Francisco CA 94080 USA;

Hop Beaujon 100 Blvd Gen Leclerc F-92110 Clichy France;

Ctr Liver Dis Inova Fairfax Med Campus 3300 Gallows Rd Falls Church VA 22042 USA;

Univ Texas Hlth Sci Ctr San Antonio Texas Liver Inst 607 Camden St Suite 108 San Antonio TX;

Charite Med Ctr Berlin Augustenburger Pl 1 D-13353 Berlin Germany;

Virginia Commonwealth Univ 1201 East Marshall St Richmond VA 23298 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词
Nonalcoholic steatohepatitis; Nonalcoholic fatty liver disease; Liver fibrosis; Cenicriviroc;

机译：非酒精性脂肪肝炎;非酒精性脂肪肝疾病;肝纤维化;CENICRIVIROC;

相似文献

外文文献
中文文献
专利

1. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design [J] . Anstee Quentin M., Neuschwander-Tetri Brent A., Wong Vincent Wai-Sun, Contemporary clinical trials . 2020,第期

机译：CENICRIVIROC用于治疗非酒精脂肪肝炎的成人肝纤维化：极光第3期研究设计
2. Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study Abstracts [J] . Sanyal Arun J., Ratziu Vlad, Harrison Stephen, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第6期

机译：Cenicriviroc安慰剂用于治疗非酒精性脂肪性肝炎并发肝纤维化：CENTAUR 2b期研究的第一年主要分析结果
3. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data [J] . Maria Paula Diaz Soto, Joseph K Lim Hepatic Medicine: Evidence and Research . 2020,第aheadaofaprint期

机译：评价春季红外毒治疗非酒精性脂肪肝炎的治疗潜力：新兴数据的简要报告
4. A Deep Learning Approach for Classifying Nonalcoholic Steatohepatitis Patients from Nonalcoholic Fatty Liver Disease Patients Using Electronic Medical Records [C] . Pradyumna Byappanahalli Suresha, Yunlong Wang, Cao Xiao, Health Intelligence Workshop;Association for the Advancement of Artificial Intelligence Annual Conference . 2020

机译：使用电子医疗记录对非酒精性脂肪肝病患者的非酒精性脂肪性肝炎患者的深入学习方法
5. Therapeutic gene delivery to human pancreatic islets for treatment of diabetes and the effect of TFO on liver fibrosis induced by bile duct ligation [D] . Panakanti, Ravikiran 2010

机译：基因治疗胰岛的治疗基因传递和三氟辛酸对胆管结扎所致肝纤维化的影响
6. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data [O] . Maria Paula Diaz Soto, Joseph K Lim 2020

机译：评价春季红外毒治疗非酒精性脂肪肝炎的治疗潜力：新兴数据的简要报告
7. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design [O] . Friedman Scott, Sanyal Arun, Goodman Zachary, 2016

机译：cenicriviroc治疗成人肝纤维化非酒精性脂肪性肝炎的疗效和安全性研究：CENTAUR 2b期研究设计

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

摘要

著录项

相似文献

相关主题

期刊订阅